National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

 Rapid Review

Commenced Completed Outcome
27/09/2013 30/10/2013 Full HTA not recommended